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Importance of monitoring and early switch to second generation tyrosine kinase
inhibitors for the prognosis of patients with chronic myeloid leukemia with
imatinib resistance or intolerance
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid
leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third
develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment
may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify
resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase
inhibitors and attainment of better results.
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Introduction
Chronic Myeloid Leukemia (CML) is a clonal hematological disease associated with
a reciprocal chromosomal translocation between chromosomes 9 and 22, resulting in the
Philadelphia (Ph) chromosome.(1) This gene fusion codes for a chimeric protein, BCR-ABL,
which is associated with the uncontrolled activity of ABL tyrosine kinase (TK). (1) The Ph
chromosome is detected in 95% of patients with CML.(2) The estimated incidence of CML
is 1 to 2 cases per 100,000 people per year.(3)
The International Randomized Study of Interferon versus STI-571 (IRIS) study
established the superiority of imatinib, an ABL kinase inhibitor, over the interferon-alpha
and cytarabine combination in terms of hematologic response (HR), cytogenetic response
(CyR) and molecular response (MolR).(4,5) Since then, imatinib is the first-line treatment of
choice for CML. The intent-to-treat analysis of the IRIS study showed an accumulated
incidence of complete cytogenetic response (CCyR) of 82.7%, event-free survival (EFS) of
81.3% and overall survival (OS) of 83.2% over 60 months.(6) Patients who reached a CyR
and a MolR during treatment showed a longer EFS and protection against progression to
the advanced phases of the disease.(7)
After seven years of follow-up of the IRIS study, 40% of patients were found to have
discontinued the treatment, and adverse events accounted for 5% of the cases, lack of
efficacy for 15%, undergoing bone marrow transplant for 3%, death for 2% and the remaining
15% withdrew for other reasons (protocol violation, consented withdrawal or non-renewal,
lost to follow-up).(8) A similar result was observed during follow-up of patients with CML
on imatinib outside a clinical trial, by the Hammersmith Hospital (De Lavallade) group. After
five years of follow-up, the EFS was 62.7%, imatinib was then suspended for nearly 40% of
the patients. The definition of event for this study was death for any cause, loss of
hematologic response or major cytogenetic response, white blood cell increase, absence of
major cytogenetic response and imatinib intolerance.
Imatinib resistance is generally due to the appearance of clones expressing mutated
forms of BCR-ABL, in which the amino acid replacements in the ABL kinase domain prevent
imatinib binding but sustain kinase activity.(9-11) In the IRIS study, the accumulated mutation
rate over five years was 8.6% (95% CI: 4.5% to 15.8%).(6) Recent studies suggest that these
mutations occur in 40% of patients with imatinib failure.(9,10,12) Soverini et al.(13) evaluated the
frequency of mutations in 297 patients with hematologic or cytogenetic resistance to imatinib.
Mutations were observed in 127 (43%) patients; 27% during the chronic phase, 52% during
the accelerated phase, 75% during myeloid blast crisis, and 83% during lymphoid blast crisis/
Ph-positive ALL. Jabbour et al. evaluated the frequency of mutations in 171 patients after
imatinib treatment failure with 66 mutations being identified in 62 (36%) patients.(14)
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Mascarenhas et al. correlated the presence of mutations
with OS in 93 imatinib resistant patients. A mutation was
detected in 25% of patients. The OS over 30 months was 87%
for patients without mutations and 56% for the mutation group
(RR = 68; p < 0.0001). Due to the association of some
mutations and imatinib resistance, it is clear that approximately
30-40% of patients will eventually need a more effective
treatment. Early detection of the presence of mutated clones
may help the therapeutic decision and the choice of alternative
treatments.(15)
Dasatinib is an ABL kinase activity inhibitor which is
different from imatinib as it binds  to both to the active and
inactive conformation in the ABL domain, in addition to
inhibiting other kinases, such as the Src family (Src, Lck, Yes,
Fyn), ckit, EphA2 and PDGPR-ß, providing lasting responses
in patients with and without BCR-ABL mutations.(16)
Dasatinib was evaluated in clinical trials (Phase I, II and III)
in adults with Ph-positive leukemias after imatinib failure or
intolerance and showed effectiveness in the chronic,
accelerated and blast phases of CML.
Dasatinib has been approved by the FDA since 2006
for CML treatment during the three phases and also for Ph-
positive ALL.
Nilotinib is a BCR-ABL kinase, c-KIT, platelet-derived
growth factor receptor (PDGFR) and ephrin receptor
inhibitor.(17) It proved to be 43 to 60 times more potent than
imatinib in cell lines. Similar to imatinib and dasatinib, nilotinib
showed no activity against T315L mutations.(18)
As imatinib, nilotinib only binds to the BCR-ABL
inactive conformation and does not inhibit Src kinases.(18)
Nilotinib has been approved by the FDA in the treatment of
patients with chronic or accelerated phase CML, who are
imatinib intolerant or resistant.(17)
Unlike dasatinib, bosutinib does not inhibit PDGFR
and c-kit.(19) It may bind both to inactive and intermediate
BCR-ABL conformations, but it does not show activity
against T315L mutations.(19) In Phase II studies it has also
demonstrated activity in patients with accelerated and blast
phase CML, previously treated with imatinib and other
TKIs.(20,21)
Monitoring CML treatment
Since imatinib was introduced, it is clear that the
appropriate monitoring of the treatment response is an
essential and relevant part of the therapeutic strategy.(22) The
objectives of monitoring minimal residual disease in CML
include: to demonstrate the efficacy of the initial treatment,
to detect treatment relapse or resistance and to identify the
mechanisms of treatment failure to help in the choice of
alternative treatments.(23)
The initial evaluation before the start of the treatment
must include the calculation of the prognosis rates using the
Sokal(24,25) or Hasford Score(26) methods and demonstrated in
Tables 1 and 2. Despite having been described in the pre-
imatinib era, they maintain an important prognostic role, even
with the use of imatinib.(4,25)
After treatment starts, for the evaluation of imatinib
response it is required that complete blood counts with
differential, cytogenetic and molecular examinations be
performed to evaluate the BCR-ABL transcript level.
Monitoring of the percentage of Ph-positive cells is the best
validated system to evaluate the response to interferon-alpha
and TKIs, as cytogenetic response is the best survival
marker.(4) Thus, cytogenetic response remains the gold
standard to evaluate CML response.(23) Notwithstanding,
most sites perform the evaluation through molecular analysis
to monitor treatment response in addition to cytogenetic
evaluation.(27-29) Reaching a major molecular response
(MMolR) after 12 months of imatinib treatment has been
associated with a longer progression-free survival (PFS).(5,7)
In general, the use of molecular studies to detect mutations
has been recommended only if there is evidence of
hematologic, cytogenetic relapse or resistance and a 2- to 5-
fold increase in BCR-ABL transcript levels.(23)
The European LeukemiaNet (ELN) updated the
recommendations published in 2006 in order to optimize and
standardize CML management.(30) The response definitions
according to the ELN are presented in Table 3.(30)
The ELN recommendations for imatinib response
monitoring are presented in Table 4.(30) Based on HR, CyR,
and MolR and time to response, imatinib overall response
can be defined as: optimal, suboptimal and absence of
response as shown in Table 5.
The recommendations further include some alert
situations. Optimal response means that switching medication
will not increase survival, which is anticipated at 100% after
six to seven years of treatment.(30) Suboptimal response means
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the patient will still receive further benefit from the continued
treatment, but the chances of optimal response are reduced.
Treatment failure suggests switching the approach, as the
chances of favorable outcomes are low.
Regarding previous recommendations,(29) a new
definition for optimal response has been introduced. In case
some type of cytogenetic response does not occur at three
months (introducing, therefore, bone marrow puncture at
this point, differing from 2006 recommendations), we
consider it a suboptimal response. In case there is no
complete hematologic response at three months, we refer to
it as failure, as well as in case no cytogenetic response is
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achieved at six months. Clonal progression during treatment
was defined as treatment failure. The deletion of the long
arm of chromosome 9, considered in previous works as an
alert signal, is no longer considered a cause for special
concern.
There is evidence in the literature claiming that early
introduction of treatment with a second generation TKI, such
as dasatinib, improves CML prognosis, making adequate
monitoring of patients using first-line medication, such as
imatinib, imperative.(31
Importance of early response in prognosis
Imatinib response is the most important prognostic
factor to achieve prolonged survival in CML.(7,32) The
response grade achieved during treatment is also an important
prognostic factor. (32) The 5-year follow-up of the IRIS study
showed longer PFS for patients who achieved a CCyR
compared to the ones who achieved only a PCyR.(7)
Sixty-nine percent of patients with early chronic phase
CML are known to achieve a CCyR after 12 months of imatinib
treatment.(4) With continued treatment, only a fraction (13%)
may still achieve this response.(7) It is controversial whether
achieving an early or delayed complete cytogenetic response
is directly related to disease progression. Some recent
analyses suggest that the risk of disease progression among
patients who achieve a CCyR during the first 12 months of
imatinib treatment is similar to that of those who achieve this
response later.(7,33)
However, other studies suggest early responses
predict a better prognosis.(4,34) In a retrospective analysis,
Quintás-Cardama et al.(32) evaluated 258 patients with
chronic phase CML regarding the probability of achieving
a CCyR, a major molecular response (MMolR) and
progression at three, six, and 12 months after imatinib was
started. The initial dose of imatinib was 800 mg/day in 208
patients and 400 mg/day in 50 patients. The probability of
achieving a CCyR or MMolR decreased significantly over
time for patients who did not achieve a CCyR at three months,
six months and 12 months, while the progression risk
increased at each assessment period. Thus, a patient who
did not achieve a CCyR at six months still had a 57%
probability of achieving this response and a 34% probability
of having an event (defined as evolution to more advanced
phases, loss of response and death). For patients who did
not achieve a CCyR up to 12 months, the probability of still
achieving this response eventually dropped to 42%, and
the risk of events increased to 38%. The authors suggest
that failure to achieve a CCyR within the first 12 months of
imatinib treatment is associated with higher disease
progression rates. The same result was seen when the
molecular response was used as response parameter. Thus,
the authors claim that the evaluation already at three months
may guide the rational use of therapeutic strategies able to
provide higher rates of CyR and MolR.
Marin et al. evaluated 224 patients with chronic phase
CML treated with imatinib regarding response and prognosis
in order to validate the 2006 ELN recommendations.(35) For
the few patients who did not achieve a CHR after three months
of treatment, the probability of achieving a CCyR was zero
(p=0.0003); OS over five years was 60% (p=0.003) and PFS
was 56% (p=0.002), thus significantly lower than those who
had achieved a CCyR.
The introduction of cytogenetic analysis at three
months is based on the data that patients who remain without
a cytogenetic response at three months have a lower
probability of achieving a CCyR with continued treatment.(6,29)
Other retrospective analyses have shown that patients who
did not achieve any cytogenetic response at six months
(Ph+ >95%) have a low probability of achieving a CCyR
(25%) or a CMolR, (12%) and are, therefore, considered
treatment failure.(6,36) In addition, patients who achieved a
CCyR at six months present higher PFS and EFS than those
with a delayed response.(37,38) The advantage of achieving a
complete cytogenetic remission at 12 months was also
evidenced in terms of OS and PFS,(6,7) as well as at 18 months
(CCyR versus PCyR, 99% versus 87% and 98% versus 76%,
respectively).(6,7)
These results suggest the early identification of high
risk patients is fundamental for a better therapeutic planning,
such as switching to second generation TKIs. The data are
clearer when cytogenetic response is considered, differently
from the data where molecular response is considered.
Cortes et al. evaluated 280 patients who achieved a
CCyR on imatinib, including 117 after interferon-alpha failure
and 163 treatment-naïve patients. Patients who did not
achieve a MMolR within 12 months of treatment had a higher
chance of losing CyR than those who achieved it (37% versus
5%; p=0.0001). Patients who achieved a decrease of ≤1-log
after three months of treatment had a lower probability of
achieving a MMolR at 24 months compared to those who
had a decrease higher than 1-log or 2-log (84% and 95%,
respectively. P=0.0002).(34)
Iacobucci et al. conducted a retrospective trial of 284
patients with late chronic phase CML treated with imatinib
400 mg daily after interferon-alpha failure. The pattern and
time to imatinib response were evaluated, comparing CyR
and MolR, PFS and OS in patients who achieved a CCyR
within one year of treatment (early responders) and in
patients with a CCyR detected after 12 months (late
responders). After three to four years of follow-up, patients
who had a delayed CyR presented a MolR rate that was
similar to that of those who had had an early CyR. No
difference was seen in the measure of residual disease
through quantitative PCR at 36 months and at 48 months
among the groups. Estimated PFS at 4 years was 88% for
early responders and 100% for late responders, while the
estimated OS was 92% and 100%, respectively. The authors
suggest that at least 12 months are required to assess
imatinib response.(33)
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A study with 120 patients with chronic phase CML
after interferon-alpha failure assessed whether early MolR
(at one and two months) measured by real time PCR could
predict or not the CyR at six months.(39) The authors
concluded that a BCR-ABL/ABL ratio < 20% after two
months of imatinib treatment was correlated to CyR at 6
months (p=0.0008).
From the studies referenced, we observed that the
exact value of MolR is more difficult to evaluate.(30) The first
analysis of the IRIS study showed that achieving a CMolR
at 12 months of treatment predicted a higher PFS.(5) However,
this difference became borderline in the subsequent analysis
(100% versus 98%; p=0.11).(7) Patients who did not achieve
a MolR during treatment are at a higher risk of losing CyR
and developing resistance to imatinib and other TKIs.(40)
Thus, the prognostic value of MMolR is still
controversial, although there is a consensus that not
achieving a MMolR and the increase in BCR-ABL transcript
levels require more careful monitoring.(6,29,37)
When to start a second generation TKI?
Quintás-Cardama et al.(31) evaluated 293 patients with
chronic phase CML and imatinib resistance as to whether
early intervention (in cytogenetic recurrence) with
dasatinib was superior to delayed intervention (in
hematologic recurrence). Out of 293 eligible patients, 151
patients had loss of major cytogenetic response (MCyR)
(Group 1), 33 patients had loss of MCyR and CHR (Group
2) and 109 patients had loss of CHR without loss of MCyR
(Group 3).
The results from dasatinib treatment may be observed
on Table 6. Among the patients with loss of MCyR during
imatinib treatment (Group 1, early intervention), 72%
achieved CCyR with dasatinib, compared to 42% of those
who had lost both responses, MCyR and CHR (Group 2,
delayed intervention) and 26% of those who lost CHR
without loss of previous MCyR (Group 3). The MMolR rate
was higher (60%) in Group 1 compared to Groups 2 (29%)
and 3 (26%). EFS at 24 months was also higher in the group
given early intervention (89% in Group 1 versus 29% in
Group 2 versus 64% in Group 3). The transformation-free
survival (TFS) for accelerated and blast phases at 24 months
was 98% in Group 1 and 93% in Group 2, while the OS was
98% and 93%, respectively. In Group 3, TFS at 24 months
was 79% and OS was 86%. The authors suggest regular
monitoring of response during imatinib treatment is essential
to identify recurrence through loss of MCyR without the
occurrence of loss of hematologic response.
Another important factor when deciding whether to
start a second generation TKI relates to mutations. The
appearance of a mutation with an imatinib resistance profile
is considered by the 2009 ELN definitions as failure and
requires switching medications. Different mutations may
confer distinct levels of resistance, depending on the
location and their effect on the kinase.(23)
Some imatinib resistance mechanisms may be
overcome by dose escalation.(41,42) A retrospective analysis
was carried out for IRIS study patients who underwent
imatinib dose escalation from 400 mg to 600 mg or 800 mg in
the event of treatment failure or suboptimal response (ELN
criteria) or according to the IRIS study criteria.(43) These
criteria included: failure to achieve CHR at three months,
failure to achieve at least a minor CyR at 12 months and loss
of major CyR at any time point. Out of 533 patients initially
randomized to receive imatinib in the IRIS study, 106 (19%)
patients had their dose escalated to 600 mg or 800 mg daily.
In this study, 67% to 86% of patients achieved or recovered
a HR, and 38% to 42% a CyR within up to 12 months after
dose escalation, depending on the failure or suboptimal
response criterion used.
The PFS for the accelerated or blast phase within three
years was 89% and the OS was 84%. Other studies, however,
suggest the escalation benefit is transient.(44, 45)
Some mutations are known to make the disease
completely resistant to imatinib, for example, the T315l
mutation. Thus, in case other mutations are acquired,
switching to a second generation TKI such as dasatinib or
nilotinib may yield superior results.(46-48)
START-R was a Phase II randomized trial comparing
dasatinib to high doses of imatinib with imatinib failure at
a conventional dose.(48) Imatinib resistant patients with
chronic phase CML at daily doses of 400 mg or 600 mg
were randomized to receive dasatinib (140 mg daily) or
imatinib at a higher dose (800 mg). This trial enrolled 150
patients with a 2:1 randomization (101 received dasatinib
and 49 received imatinib). The primary endpoint analyzed
was the MCyR rate over 12 months and the secondary
endpoints were the MCyR and CHR rates at any period
before cross-over, duration of the MCyR and CHR and
time to MCyR and CHR before cross-over. The endpoints
were also evaluated after cross-over. The response rates
are illustrated in Table 3. The mean time to treatment failure
was longer for dasatinib, with an 84% decrease in relative
risk (HR=0.16; 95% CI=0.1 to 0.26; p<0.001). Progression-
free survival was also favorable towards dasatinib, with
an 86% decrease in relative risk (HR=0.14; 95% CI=0.05 to
0.4; p<0.001).(49)
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Kantarjian et al. published a phase II study with a
2-year follow-up, demonstrating that dasatinib sustained
higher responses (Table 7) compared to high doses of
imatinib, in addition to longer progression-free survival
(p=0.0012).(50)
Thus, an investigation of mutations in patients during
progression is fundamental when planning the best
therapeutic strategy. The presence of the T315l mutation
confers resistance both to imatinib and to second generation
TKIs, such as dasatinib and nilotinib.(51) Although there is
no head-to-head comparison of the efficacy of second
generation agents, the identification of specific mutations
could help towards the choice of best option.(30,51)
Conclusions
 The introduction of TKIs had an important impact on
the prognosis of patients with CML over the last years. The
rising increase of effective therapeutic options justifies the
need for adequate monitoring, for the choice of the best
second-line treatment option and its introduction at the most
adequate time point. In the same manner that CML treatment
has been rapidly evolving, the concepts related to monitoring,
including the available techniques and the interpretation of
their results, in addition to the best use of all this information,
also evolve constantly.
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